BSJ-04-132 is a Selective Ribociclib-Based CDK4 Degrader (PROTAC)
Targeted protein degradation induced by PROTAC has become a new therapeutic strategy in drug development. Besides, PROTAC has two covalently linked protein binding molecules. One can bind E3 ubiquitin ligases…